DOCSLIB.ORG

Repeated Administration of the Substituted Amphetamine P

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Repeated Administration of the Substituted Amphetamine P European Journal of Pharmacology 546 (2006) 74–81 www.elsevier.com/locate/ejphar Repeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine ⁎ Paul D. Callaghan a,b, Kirsten Farrand a, Abdallah Salem a, , Patrick Hughes a, Lynette C. Daws a,b, Rodney J. Irvine a a Discipline of Pharmacology, School of Medical Sciences, Medical School North, The University of Adelaide, Adelaide, South Australia, 5005, Australia b Department of Physiology, The University of Texas Health Science Center at San Antonio, TX, USA Received 30 May 2006; received in revised form 13 July 2006; accepted 17 July 2006 Available online 25 July 2006 Abstract Worldwide growth in p-methoxyamphetamine (PMA) usage amongst ‘ecstasy’ users indicates a proportionally greater incidence of acute toxicity compared to 3,4-methylenedioxymethamphetamine (MDMA). While longer-term use of MDMA appears to produce degeneration of 5- hydroxytryptamine (5-HT, serotonin) neurons, PMA effects are poorly understood. The aim of this study was to determine the effect of repeated PMA administration on two indices of 5-HT axonal degeneration, cortical brain 5-HT transporter (SERT) density and 5-HT/5-hydroxyindolacetic acid (5-HIAA) content. Treatment of male rats once daily for 4 days (10 or 20 mg/kg) with PMA or MDMA resulted in significant reductions (20 mg/kg: 53% and 23% of vehicle treatment respectively) in [3H]-paroxetine binding (SERT density) one week after final drug administration. When rats were housed at a higher ambient temperature (28 °C vs. 22 °C) for 6 h after dosing, no additive effect was seen for either drug. A more intensive dosing regimen (10 or 20 mg/kg twice daily for 4 days) was used to examine PMA/MDMA effects on cortical 5-HT content. Two weeks after MDMA treatment, significant reductions in cortical 5-HT content (20 mg/kg: 39% of vehicle treatment) were seen. However, PMA did not alter cortical 5-HT content, yet reduced cortical 5-HIAA content (20 mg/kg: 72% of vehicle treatment). These data suggest PMA has severe long- term implications clinically for alteration of 5-HT neurotransmission that may differ from MDMA, but may not necessarily be interpreted as a degeneration of 5-HT fibres. © 2006 Elsevier B.V. All rights reserved. Keywords: Para-methoxyamphetamine; 3,4-methylenedioxymethamphetamine; Serotonin transporter; Neurodegeneration; 5-HT 1. Introduction structure of these compounds, sold under the collective name “ecstasy”, are most commonly based on the amphetamine Recreational use of substituted amphetamines has grown molecule, with the most widespread example being 3,4- exponentially since the mid 1980s, leading to a proliferation of methylenedioxymethamphetamine (MDMA). Of considerable compounds possessing a unique mixture of euphoric and concern is the significant risk when using ‘ecstasy’ of acute stimulant properties, popular within ‘dance party culture’. The toxicity, resulting from a severe hyperthermic response, which can lead to rhabdomyolysis and coma (Green et al., 2003). Additionally, drugs from this class have varying abilities to induce degeneration of monoaminergic systems within the ⁎ Corresponding author. Tel.: +61 8 8303 4327; fax: +61 8 8224 0685. E-mail address: [email protected] (A. Salem). brain, which is thought to be responsible for cognitive deficits URL: http://www.adelaide.edu.au/health/pharm/staff/asalem.html seen with regular ‘ecstasy’ use clinically (Green et al., 2003; (A. Salem). Parrott, 2001). 0014-2999/$ - see front matter © 2006 Elsevier B.V. All rights reserved. doi:10.1016/j.ejphar.2006.07.011 P.D. Callaghan et al. / European Journal of Pharmacology 546 (2006) 74–81 75 p-Methoxyamphetamine (PMA) is a substituted amphetamine examine the effects of PMA at more pharmacologically relevant that is usually sold as ‘ecstasy’,andhasbeenlinkedwithan doses, and also in other brain regions relevant to understanding apparent higher incidence of acute hyperthermia and toxicity than the cognitive deficits seen in regular substituted amphetamine seen for MDMA (Byard et al., 2002; White et al., 1997). While users. initially appearing in Canada in 1973 (Cimbura, 1974), its use has The primary aim of this study was to determine if repeated only become widespread since 1994 in Australia, where it is PMA treatment does indeed alter indices of 5-HT and/or responsible for most ‘ecstasy’-related deaths (Byard et al., 2002; dopamine presynaptic terminal viability. First, rats were treated Felgate et al., 1998). More recently, PMA use has been reported in once per day for 4 days with vehicle, PMA or MDMA (10 or USA and Europe where again an increased incidence of acute 20 mg/kg) and one week after the final dose, [3H]-paroxetine morbidity has been noted (Becker et al., 2003; Chodorowski et al., binding was measured in cortical membrane preparations. This 2002; Dams et al., 2003; Galloway and Forrest, 2002; Johansen measure has been shown to be a sensitive measure of 5-HT et al., 2003; Kraner et al., 2001; Lora-Tamayo et al., 2004; presynaptic terminal loss (Battaglia et al., 1987). Additionally, Refstad, 2003; Voorspoels et al., 2002). MDMA effects on neurodegeneration of 5-HT fibres are poten- These acute effects of both PMA and MDMA are mediated tiated by elevated ambient temperature during drug adminis- by their interaction with either the 5-hydroxytryptamine (5-HT, tration (Malberg and Seiden, 1998). This is of particular serotonin) transporter (SERT) and/or the dopamine transporter relevance due to the high ambient temperature in environments (DAT) to evoke release of 5-HT and/or dopamine, and inhibit where “ecstasy” is used recreationally. In order to examine if neurotransmitter uptake from presynaptic sites within the cen- any additive effect of ambient temperature was seen, animals tral nervous system (Callaghan et al., 2005; Daws et al., 2000; were maintained at an ambient temperature of either 22 °C Freezer et al., 2005; Gough et al., 2002; Green et al., 2003; (room temperature) or 28 °C for 6 h after each PMA, MDMA or Kaminskas et al., 2002; McKenna and Peroutka, 1990; Menon vehicle dose. The once daily treatment regimen was chosen as et al., 1976). Both the acute euphoric effects and detrimental MDMA has been shown previously to alter cortical [3H]- effects of hyperthermia and serotonergic syndrome are all paroxetine binding with this regimen (O'Shea et al., 1998). thought to be due to the acute actions of these drugs on 5-HT Additionally, the pharmacokinetic parameters of the drugs vary neurotransmission (Green et al., 1995). However the distinctly considerably (Farre et al., 2004; Kitchen et al., 1979; Lim and different neurodegenerative effects resulting from long term Foltz, 1988), and a single daily dose would simplify the inter- usage of these drugs appear far more insidious. MDMA pro- pretation of any effect of the 6 h alteration in ambient environ- duces dose dependent selective degeneration of 5-HT axonal ment after each dose of drug. terminals as little as one week after cessation of use in rodents If there were indeed a loss in presynaptic monoaminergic and primates (Battaglia et al., 1988, 1987; Hewitt and Green, terminals with PMA treatment, it would be expected, like 1994; Lew et al., 1996; O'Hearn et al., 1988; O'Shea et al., MDMA, that there would be a corresponding loss in neuro- 1998; Sabol et al., 1996; Scanzello et al., 1993; Schmidt, 1987). transmitter and subsequent metabolites. As such, cortical This has been demonstrated in rats using indices of 5-HT axonal changes in dopamine/3,4-dihydroxyphenylacetic acid degeneration, such as a reduction in forebrain 5-HT, the 5-HT (DOPAC) and 5-HT/5-HIAA content were measured. However, metabolite 5-hydroxyindolacetic acid (5-HIAA) and reduction for this experiment a higher and more frequent dosing regimen in [3H]-paroxetine binding (a selective ligand for SERT). These was chosen, based on MDMA treatments that have been pre- effects are demonstrated indirectly in human subjects who reg- viously reported to produce maximal effects (Commins et al., ularly use ‘ecstasy’ through reductions in cerebrospinal fluid 1987; O'Hearn et al., 1988). Rats were treated twice daily for (CSF) levels of the 5-HIAA, reduced markers of 5-HT terminals 4 days (10 or 20 mg/kg), then two weeks after the final dose, using PET ligands and various cognitive deficits (McCann cortex was removed and frozen for later measurement of 5-HT/ et al., 1999, 1994; Morgan, 2000; Parrott, 2001; Vollenweider 5-HIAA/dopamine/DOPAC by high-performance liquid chro- et al., 2002). matography assay with electrochemical detection (HPLC-ED). In contrast, the potential for PMA to induce degeneration of monoaminergic fibres within the central nervous system is not 2. Materials and methods clear. An initial study by Steele and co-workers showed that one week after a high dose of PMA (80 mg/kg, twice daily for 2.1. Animals 4 days), forebrain 5-HT and 5-HIAA concentrations were sig- nificantly reduced (Steele et al., 1992). However, the interpre- All experiments were approved by the institutional animal tation of this finding is complicated by the dose used being well care and use committee at the University of Adelaide, and were in excess of the acute LD50 for PMA (Nichols et al., 1975; in strict accordance with the NHMRC guidelines for the Care Steele et al., 1992). Findings from our laboratory indicate re- and Use of Laboratory Animals. Male Sprague–Dawley rats peated PMA treatment resulted in reductions in hippocampal 250–400 g, were obtained from Laboratory Animal Services SERT binding and synaptosomal 5-HT uptake, but not 5-HT (University of Adelaide, Australia). They were housed in content (Callaghan et al., in press). This was in contrast to the groups of three under a 12:12 light/dark cycle, at a constant effects of repeated MDMA treatment, which resulted in a re- temperature of 20±2 °C; food and water were available ad duction in hippocampal SERT binding, synaptosomal 5-HT libitum.
Load more

Recommended publications
  • Selective Labeling of Serotonin Receptors Byd-[3H]Lysergic Acid
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 5783-5787, December 1978 Biochemistry Selective labeling of serotonin receptors by d-[3H]lysergic acid diethylamide in calf caudate (ergots/hallucinogens/tryptamines/norepinephrine/dopamine) PATRICIA M. WHITAKER AND PHILIP SEEMAN* Department of Pharmacology, University of Toronto, Toronto, Canada M5S 1A8 Communicated by Philip Siekevltz, August 18,1978 ABSTRACT Since it was known that d-lysergic acid di- The objective in this present study was to improve the se- ethylamide (LSD) affected catecholaminergic as well as sero- lectivity of [3H]LSD for serotonin receptors, concomitantly toninergic neurons, the objective in this study was to enhance using other drugs to block a-adrenergic and dopamine receptors the selectivity of [3HJISD binding to serotonin receptors in vitro by using crude homogenates of calf caudate. In the presence of (cf. refs. 36-38). We then compared the potencies of various a combination of 50 nM each of phentolamine (adde to pre- drugs on this selective [3H]LSD binding and compared these clude the binding of [3HJLSD to a-adrenoceptors), apmo ie, data to those for the high-affinity binding of [3H]serotonin and spiperone (added to preclude the binding of [3H[LSD to (39). dopamine receptors), it was found by Scatchard analysis that the total number of 3H sites went down to 300 fmol/mg, compared to 1100 fmol/mg in the absence of the catechol- METHODS amine-blocking drugs. The IC50 values (concentrations to inhibit Preparation of Membranes. Calf brains were obtained fresh binding by 50%) for various drugs were tested on the binding of [3HLSD in the presence of 50 nM each of apomorphine (A), from the Canada Packers Hunisett plant (Toronto).
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters
    '4 0026-895X/93/061227-05503.00/0 Copyright © by The American Society for Pharmacology and Experimental Therapeutics AIl rights of reproduction in any form reserved. MOLECULAR PHARMACOLOGY, 44:1227-1231 Amphetamine Derivatives Interact with Both Plasma Membrane and Secretory Vesicle Biogenic Amine Transporters SHIMON SCHULDINER, SONIA STEINER-MORDOCH, RODRIGO YELIN, STEPHEN C. WALL, and GARY RUDNICK Departmentof Pharmacology,YaleUniversitySchool of Medicine,New Haven,CT 06510 (S.C.W.,G.R.) andAlexanderSilbermanInstituteof Life Sciences,TheHebrew University,GivatRam, Jerusalem,Israel (S.S.,S.S.-M., R.Y.) ReceivedJune 7, 1993; Accepted September 16, 1993 SUMMARY The interaction of fenfluramine, 3,4-methylenedioxymethamphe- porter, fenfiuramine inhibited serotonin transport and dissipated tamine (MDMA), and p-chloroamphetamine (PCA) with the plate- the transmembrane pH difference (ApH) that drives amine up- let plasma membrane serotonin transporter and the vesicular take. The use of [3H]reserpine-binding measurements to deter- amine transporter were studied using both transport and binding mine drug interaction with the vesicular amine transporter al- measurements. Fenfluramine is apparently a substrate for the lowed assessment of the relative ability of MDMA, PCA, and plasma membrane transporter, and consequently inhibits both fenfluramine to bind to the substrate site of the vesicular trans- serotonin transport and imipramine binding. Moreover, fenflura- porter. These measurements permit a distinction between inhi- mine exchanges with internal [3H]serotonin in a plasma mem- bition of vesicular serotonin transport by directly blocking vesic- brane transporter-mediated reaction that requires NaCI and is ular amine transport and by dissipating ApH. The results indicate blocked by imipramine. These properties are similar to those of that MDMA and fenfluramine inhibit by both mechanisms but MDMA and PCA as previously described.
    [Show full text]
  • Ring-Substituted Amphetamine Interactions with Neurotransmitter Receptor Binding Sites in Human Cortex
    208 NeuroscienceLetters, 95 (1988) 208-212 Elsevier Scientific Publishers Ireland Ltd. NSL O5736 Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex Pamela A. Pierce and Stephen J. Peroutka Deparmentsof Neurologyand Pharmacology, Stanford University Medical Center, StanJbrd,CA 94305 (U.S.A.) (Received 31 May 1988; Revised version received 11 August 1988; Accepted 12 August 1988) Key words.' Ring-substituted amphetamine; (_+)-3,4-Methylenedioxyamphetamine; ( +_)-3,4-Methylene- dioxyethamphetamine; (_+)-3,4-Methylenedioxymethamphetamine; Ecstasy; 4-Bromo-2,5- dimethoxyphenylisopropylamine binding site; Human cortical receptor The binding affinities of 3 ring-substituted amphetamine compounds were determined at 9 neurotrans- mitter binding sites in human cortex. (_+)-3,4-Methylenedioxyamphetamine (MDAk (_+)-3,4-methylene- dioxyethamphetamine (MDE), and (_+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') all display highest affinity (approximately 1 /tM) for the recently identified 'DOB binding site' labeled by ['TBr]R(-)4-bromo-2,5-dimethoxyphenylisopropylamine ([77Br]R(-)DOB). MDA displays moderate affinity (4-5/iM) for the 5-hydroxytryptaminetA (5-HTr^), 5-HT_D,and =,-adrenergic sites in human cor- tex. MDE and MDMA display lower affinity or are inactive at all other sites tested in the present study. These observations are discussed in relation to the novel psychoactive effects of the ring-substituted amphetamines. A series of ring-substituted amphetamine derivatives exist which are structurally related to both amphetamines and hallucinogens. However, drugs such as (+)-3,4- methylenedioxyamphetamine (MDA), (_+)-3,4-methylenedioxyethamphetamine (MDE), and (+)-3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') ap- pear to produce unique psychoactive effects which are distinct from the effects of both amphetamines and hallucinogens [13, 15].
    [Show full text]
  • Differentially Affect Monoamine Transporters and Abuse Liability
    Neuropsychopharmacology (2017) 42, 1950–1961 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse Liability Ernesto Solis Jr1, John S Partilla2, Farhana Sakloth3, Iwona Ruchala4, Kathryn L Schwienteck5, 4 4 3 5 *,2 Louis J De Felice , Jose M Eltit , Richard A Glennon , S Stevens Negus and Michael H Baumann 1In Vivo Electrophysiology Unit, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA; 2Designer Drug Research Unit, Intramural Research Program, National Institute on Drug Abuse, 3 National Institutes of Health, Baltimore, MD, USA; Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; 4 5 Department of Physiology and Biophysics, Virginia Commonwealth University, Richmond, VA, USA; Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA Clandestine chemists synthesize novel stimulant drugs by exploiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and serotonin (DAT, NET, and SERT, respectively). 4-Methylamphetamine (4-MA) is an emerging drug of – abuse that interacts with transporters, but limited structure activity data are available for its analogs. Here we employed uptake and release assays in rat brain synaptosomes, voltage-clamp current measurements in cells expressing transporters, and calcium flux assays in cells coexpressing transporters and calcium channels to study the effects of increasing N-alkyl chain length of 4-MA on interactions at DAT, NET, and SERT. In addition, we performed intracranial self-stimulation in rats to understand how the chemical modifications affect abuse liability.
    [Show full text]
  • MDMA, MBDB' and I! I the Classichallucinogens
    Differences Between the Mechanism I t of Action of MDMA, MBDB' and i! I the ClassicHallucinogens. i Identification of a New Therapeutic Class: Entactogens Jawi'ri", ! 7 U$ DAVID E. NICHOLS, PH.D.* The widespread use of psychedelic drugs, such as quantitative structure-activity relationships (QSARs). lysergic ac;.d diethylamide (LSD), during the 1960's and Simply stated, attempts are made to find quantitative 1970's IcC to severe reactions by governmental agencies correlations (or equations) that relate biological activity to and proscriptions against their use. However, with the fundamental properties of the molecule. This approach is high deg _e of interest in mind-altering drugs in the being widely developed in the pharmaceutical industry in United States, as evidenced by their widespread popular- order to understand more fully how particular types of ity, it wasonlyamatteroftimebeforenewdrugsappeared drugs work, and to be able to predict which additional that were developed outside of the pharmaceutical corn- molecules should be synthesized. It should also be added panics, that no equations have been developed that adequately j Nearly 70 years after its first synthesis, 3,4- correlate hallucinogenic or psychedelic activity with any methy'enedioxymethamphetamine (MDMA) was redis- particular molecular property. covered. Although it had its' more recent origin in the class In this context, it is important to define clearly the of dr. gs that is generally defined as psychedelic or hallu- type of biological activity that is being measured. It is cino enic, it clearly appears different from LSD. In hu- typical that if a molecule has several different sites of mar , MDMA induces a state of reduced anxiety and action in the brain, that each oneof these actions may be lc .red defensiveness that makes it attractive to thera- related to entirely different structural features or proper- pi .
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • Summary of Risk Management Plan for Fintepla (Fenfluramine) This Is a Summary of the Risk Management Plan (RMP) for Fintepla
    Summary of risk management plan for Fintepla (fenfluramine) This is a summary of the risk management plan (RMP) for Fintepla. The RMP details important risks of Fintepla, how these risks can be minimised, and how more information will be obtained about Fintepla's risks and uncertainties (missing information). Fintepla's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Fintepla should be used. This summary of the RMP for Fintepla should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR). Important new concerns or changes to the current ones will be included in updates of Fintepla's RMP. I. The medicine and what it is used for Fintepla is authorised for the treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older (see SmPC for the full indication). It contains fenfluramine as the active substance and it is given by mouth. Further information about the evaluation of Fintepla’s benefits can be found in Fintepla’s EPAR, including in its plain-language summary, available on the EMA website, under the medicine’s webpage https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla. II. Risks associated with the medicine and activities to minimise or further characterise the risks Important risks of Fintepla, together with measures to minimise such risks and the proposed studies for learning more about Fintepla's risks, are outlined below.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • 212102Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 212102Orig1s000 OTHER REVIEW(S) Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research | Office of Surveillance and Epidemiology (OSE) Epidemiology: ARIA Sufficiency Date: June 29, 2020 Reviewer: Silvia Perez-Vilar, PharmD, PhD Division of Epidemiology I Team Leader: Kira Leishear, PhD, MS Division of Epidemiology I Division Director: CAPT Sukhminder K. Sandhu, PhD, MPH, MS Division of Epidemiology I Subject: ARIA Sufficiency Memo for Fenfluramine-associated Valvular Heart Disease and Pulmonary Arterial Hypertension Drug Name(s): FINTEPLA (Fenfluramine hydrochloride, ZX008) Application Type/Number: NDA 212102 Submission Number: 212102/01 Applicant/sponsor: Zogenix, Inc. OSE RCM #: 2020-953 The original ARIA memo was dated June 23, 2020. This version, dated June 29, 2020, was amended to include “Assess a known serious risk” as FDAAA purpose (per Section 505(o)(3)(B)) to make it consistent with the approved labeling. The PMR development template refers to the original memo, dated June 23, 2020. Page 1 of 13 Reference ID: 46331494640015 EXECUTIVE SUMMARY (place “X” in appropriate boxes) Memo type -Initial -Interim -Final X X Source of safety concern -Peri-approval X X -Post-approval Is ARIA sufficient to help characterize the safety concern? Safety outcome Valvular Pulmonary heart arterial disease hypertension (VHD) (PAH) -Yes -No X X If “No”, please identify the area(s) of concern. -Surveillance or Study Population X X -Exposure -Outcome(s) of Interest X X -Covariate(s) of Interest X X -Surveillance Design/Analytic Tools Page 2 of 13 Reference ID: 46331494640015 1.
    [Show full text]
  • Synergistic Interactions Between Fenfluramine and Phentermine
    International Journal of Obesity (1999) 23, 723±732 ß 1999 Stockton Press All rights reserved 0307±0565/99 $12.00 http://www.stockton-press.co.uk/ijo Synergistic interactions between Fen¯uramine and Phentermine PJ Wellman1* and TJ Maher2 1Behavioral Neuroscience Program, Texas A&M University, College Station, Texas 77843-4235, USA and 2Division of Pharmaceutical Sciences, Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Avenue, Boston, Massachusetts 02115, USA `Fen-phen' refers to the off-label combination of the appetite suppressants fen¯uramine and phentermine. The rationale for the fen-phen combination was that the two drugs exerted independent actions on brain satiety mechanisms so that it was possible to use lower doses of each drug and yet retain a common action on suppressing appetite while minimizing adverse drug effects. The focus of the present review is to consider whether fen¯uramine and phentermine exert actions that are additive in nature or whether these two drugs exhibit drug-drug synergism. The fen-phen combination results in synergism for the suppression of appetite and body weight, the reduction of brain serotonin levels, pulmonary vasoconstriction and valve disease. Fen-phen synergism may re¯ect changes in the pharmacokinetics of drug distribution, common actions on membrane ion currents, or interactions between neuronal release and reuptake mechanisms with MAO-mediated transmitter degradation. The synergism between fen¯uramine and phentermine highlights the need to more completely understand the pharmacology and neurochemistry of appetite suppressants prior to use in combination pharmacotherapy for the treatment of obesity. Keywords: monoamine oxidase inhibitors; serotonin; drug-drug interactions; isobologram Introduction lost during treatment with an appetite suppressant is quickly regained when the drug is terminated.
    [Show full text]